283 related articles for article (PubMed ID: 10208998)
1. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density.
Zambon A; Hokanson JE; Brown BG; Brunzell JD
Circulation; 1999 Apr; 99(15):1959-64. PubMed ID: 10208998
[TBL] [Abstract][Full Text] [Related]
2. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.
Brown G; Albers JJ; Fisher LD; Schaefer SM; Lin JT; Kaplan C; Zhao XQ; Bisson BD; Fitzpatrick VF; Dodge HT
N Engl J Med; 1990 Nov; 323(19):1289-98. PubMed ID: 2215615
[TBL] [Abstract][Full Text] [Related]
3. Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment.
Zambon A; Deeb SS; Brown BG; Hokanson JE; Brunzell JD
Circulation; 2001 Feb; 103(6):792-8. PubMed ID: 11171785
[TBL] [Abstract][Full Text] [Related]
4. Use of niacin, statins, and resins in patients with combined hyperlipidemia.
Brown BG; Zambon A; Poulin D; Rocha A; Maher VM; Davis JW; Albers JJ; Brunzell JD
Am J Cardiol; 1998 Feb; 81(4A):52B-59B. PubMed ID: 9526815
[TBL] [Abstract][Full Text] [Related]
5. Genetically determined apo B levels and peak LDL density predict angiographic response to intensive lipid-lowering therapy.
Zambon A; Brown BG; Hokanson JE; Motulsky AG; Brunzell JD
J Intern Med; 2006 Apr; 259(4):401-9. PubMed ID: 16594908
[TBL] [Abstract][Full Text] [Related]
6. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol.
Stewart BF; Brown BG; Zhao XQ; Hillger LA; Sniderman AD; Dowdy A; Fisher LD; Albers JJ
J Am Coll Cardiol; 1994 Mar; 23(4):899-906. PubMed ID: 8106695
[TBL] [Abstract][Full Text] [Related]
7. Effect of lovastatin or niacin combined with colestipol and regression of coronary atherosclerosis.
Brown BG
Eur Heart J; 1992 Jul; 13 Suppl B():17-20. PubMed ID: 1644095
[TBL] [Abstract][Full Text] [Related]
8. Successful management of primary hypercholesterolaemia with simvastatin and low-dose colestipol.
Simons LA; Simons J; Parfitt A
Med J Aust; 1992 Oct; 157(7):455-9. PubMed ID: 1406395
[TBL] [Abstract][Full Text] [Related]
9. Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia.
Malloy MJ; Kane JP; Kunitake ST; Tun P
Ann Intern Med; 1987 Nov; 107(5):616-23. PubMed ID: 3662275
[TBL] [Abstract][Full Text] [Related]
10. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
Bays HE; Dujovne CA; McGovern ME; White TE; Kashyap ML; Hutcheson AG; Crouse JR;
Am J Cardiol; 2003 Mar; 91(6):667-72. PubMed ID: 12633795
[TBL] [Abstract][Full Text] [Related]
11. Combination drug therapy for familial combined hyperlipidemia.
East C; Bilheimer DW; Grundy SM
Ann Intern Med; 1988 Jul; 109(1):25-32. PubMed ID: 3288029
[TBL] [Abstract][Full Text] [Related]
12. Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy.
Schrott HG; Stein EA; Dujovne CA; Davidson MH; Goris GB; Oliphant TH; Phillips JC; Shawaryn GG
Am J Cardiol; 1995 Jan; 75(1):34-9. PubMed ID: 7801861
[TBL] [Abstract][Full Text] [Related]
13. Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Treatment Study-Observational Study.
Zhao XQ; Phan BA; Davis J; Isquith D; Dowdy AA; Boltz S; Neradilek M; Monick EA; Brockenbrough A; Hus-Frechette EE; Albers JJ; Brown BG
J Clin Lipidol; 2016; 10(5):1091-7. PubMed ID: 27678425
[TBL] [Abstract][Full Text] [Related]
14. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease.
Brown BG; Bardsley J; Poulin D; Hillger LA; Dowdy A; Maher VM; Zhao XQ; Albers JJ; Knopp RH
Am J Cardiol; 1997 Jul; 80(2):111-5. PubMed ID: 9230143
[TBL] [Abstract][Full Text] [Related]
15. Effects of colestipol alone and in combination with simvastatin on apolipoprotein B metabolism.
Gaw A; Packard CJ; Lindsay GM; Murray EF; Griffin BA; Caslake MJ; Colquhoun I; Wheatley DJ; Lorimer AR; Shepherd J
Arterioscler Thromb Vasc Biol; 1996 Feb; 16(2):236-49. PubMed ID: 8620338
[TBL] [Abstract][Full Text] [Related]
16. Effects of intensive lipid-lowering therapy on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B.
Zhao XQ; Brown BG; Hillger L; Sacco D; Bisson B; Fisher L; Albers JJ
Circulation; 1993 Dec; 88(6):2744-53. PubMed ID: 8252687
[TBL] [Abstract][Full Text] [Related]
17. Hepatic lipase as a focal point for the development and treatment of coronary artery disease.
Zambon A; Brown BG; Deeb SS; Brunzell JD
J Investig Med; 2001 Jan; 49(1):112-8. PubMed ID: 11217140
[TBL] [Abstract][Full Text] [Related]
18. The effect of the apolipoprotein E phenotype on cholesteryl ester transfer protein activity, plasma lipids and apolipoprotein A I levels in hypercholesterolaemic patients on colestipol and lovastatin treatment.
Korhonen T; Hannuksela ML; Seppänen S; Kervinen K; Kesäniemi YA; Savolainen MJ
Eur J Clin Pharmacol; 1999 Feb; 54(12):903-10. PubMed ID: 10192749
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of efficacy and safety of fixed dose lovastatin and niacin(ER) combination in asian Indian dyslipidemic patients: a multicentric study.
Sharma M; Sharma DR; Singh V; Panwar RB; Hira HS; Mohan B; Kumar N; Sharma SK; Gupta R
Vasc Health Risk Manag; 2006; 2(1):87-93. PubMed ID: 17319473
[TBL] [Abstract][Full Text] [Related]
20. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up.
Cashin-Hemphill L; Mack WJ; Pogoda JM; Sanmarco ME; Azen SP; Blankenhorn DH
JAMA; 1990 Dec; 264(23):3013-7. PubMed ID: 2243429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
